Arthrosi Announces Multiple Presentations at the American College of Rheumatology (ACR) Convergence 2023
16 Oct 2023
Phase 3
SAN DIEGO, Oct. 16, 2023 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a clinical-stage biotechnology company developing treatments to reduce uric acid levels, dissolve uric acid crystals and prevent joint damage in gout patients, today announced the acceptance of three poster presentations and one late breaking oral presentation at the American College of Rheumatology (ACR) Convergence 2023 meeting, being held in San Diego, CA on November 10-15, 2023.
Details for the presentations are as follows:
Oral Presentation:
Title: AR882, an Efficacious and Selective URAT1 InhibitorURAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
Session Title: Late-Breaking Abstracts
Abstract Number: #1651889
Date/Time: Wednesday, November 15 / 7:30 AM - 7:45 AM
Poster Presentations:
Title: Efficacy and Safety of AR882, a Selective Uric Acid Transporter 1 (URAT1) Inhibitor, in Gout Patients with Various Baseline Characteristics Following 12-Week Treatment in Patients
Session Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I
Abstract Number: #1553555
Date/Time: Sunday, November 12 / 9:00am-11:00am PST
Session Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
Abstract Number: #1553704
Date/Time: Monday, November 13 / 9:00am-11:00am PST
Title: AR882, A Potent Uricosuric Agent, Shows Favorable Uric Acid Excretion Profile Following Multiple Doses
Session Title: Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
Abstract Number: #1552575
Date/Time: Monday, November 13 / 9:00-11:00am PST
About Gout:
In the U.S., an estimated 10 million individuals are diagnosed with gout. Gout is a form of inflammatory arthritis that can significantly diminish mobility, functionality, and overall quality of life. Gout emerges from the crystallization of uric acid within the joints and soft tissue, instigating painful flare-ups and chronic symptoms. The kidneys play a pivotal role in the process, as they are responsible for filtering out and excreting uric acid from the body. Elevated sUA levels often signify an imbalance in production or excretion of uric acid, and acts as an early indicator of potential gout development. Consistent, elevated sUA levels have been identified as a precursor to gout attacks and related complications. It's essential to monitor and manage sUA levels as part of comprehensive gout treatment and prevention strategies.
About Arthrosi:
Arthrosi Therapeutics, Inc., headquartered in San Diego, CA, was established in 2018. The company's goal is to develop potential treatments aimed at uric acid levels and minimizing joint damage for gout patients. Arthrosi anticipates initiating pivotal phase 3 program in early 2024.
Media Contact:
Shunqi Yan, PhD
Founder & Chief Operating Officer
[email protected]
Investor Contact:
Stern Investor Relations, Inc.
Alex Lobo
212-698-8802
[email protected]
SOURCE Arthrosi Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.